Table 3b.

Genetic Disorders Associated with Renal Cell Carcinoma

GeneDisorderMOIClinical Characteristics
FH FH tumor predisposition syndrome ADCharacterized by cutaneous leiomyomata, uterine leiomyomata (fibroids), &/or renal tumors. Pheo & PGL have been described in small number of families. Median age of detection is ~40 yrs.
FLCN Birt-Hogg-Dubé syndrome ADCutaneous manifestations (fibrofolliculomas, acrochordons, angiofibromas, oral papules, cutaneous collagenomas, & epidermal cysts), pulmonary cysts/history of pneumothorax, & various types of renal tumors. Median age of renal tumor diagnosis is 48 yrs.

AD = autosomal dominant; MOI = mode of inheritance; Pheo = pheochromocytomas; PGL = paragangliomas

From: Von Hippel-Lindau Syndrome

Cover of GeneReviews®
GeneReviews® [Internet].
Adam MP, Feldman J, Mirzaa GM, et al., editors.
Seattle (WA): University of Washington, Seattle; 1993-2025.
Copyright © 1993-2025, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2025 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.